

PRESS RELEASE

STOCKHOLM, 16 JUNE 2026 14:14 CEST

Utilization of authorization to acquire own shares

The Board of RaySearch Laboratories AB (publ) has resolved to utilize the authorization to acquire the company's own shares granted by the 2026 Annual General Meeting, with the aim of ensuring the delivery of shares to participants in the company's performance based long-term incentive program (LTI 2026).

The Board's resolution concerns the acquisition of up to 380,000 own Class B shares during the period from and including June 16, 2026 up until the 2027 Annual General Meeting, on one or several occasions.

Acquisitions will be made on Nasdaq Stockholm pursuant to Nasdaq Stockholm's Nordic Main Market Rulebook for Issuers of Shares, and in compliance with the pricing restrictions set out therein.

RaySearch currently holds no own shares. Completed acquisitions will be reported to Nasdaq Stockholm in accordance with applicable rules.

For more information, please contact

Carolina Strömlid, Head of Investor Relations, RaySearch Laboratories AB

Tel: +46 (0) 708 807 173

ir@raysearchlabs.com

About RaySearch

RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems. RaySearch's software has been sold to over 1,200 clinics in 51 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003 (STO: RAY B). More information is available at raysearchlabs.com.

Learn more about us on:

[LinkedIn](#)

[YouTube](#)

** Subject to regulatory clearance in some markets.*